Lopinavir/Ritonavir + Atorvastatin |
32 |
F |
CYP3A4
inhibitors2 may increase the serum concentration of
atorvastatin |
Start with the lowest possible atorvastatin dose, monitor
for signs and symptoms of toxicity |
Aspirin + Enoxaparin |
13 |
F |
Antiplatelet agents may enhance the
anticoagulant effect of Enoxaparin |
Monitor closely for signs and
symptoms of bleeding |
Lopinavir/Ritonavir + Alprazolam |
10 |
G |
CYP3A4 inhibitors may
increase the serum concentration of alprazolam |
Consider using an
alternative |
Clopidogrel + Enoxaparin |
5 |
F |
Antiplatelet agents may enhance the
anticoagulant effect of enoxaparin |
Monitor closely for signs and
symptoms of bleeding |
Lopinavir/Ritonavir + Dexamethasone |
5 |
F |
CYP3A4 inhibitors may
increase the serum concentration of dexamethasone |
Monitor for
increased adverse effects of dexamethasone, consider dose
reduction |
Lopinavir/Ritonavir + Prednisolone |
5 |
F |
CYP3A4 Inhibitors may
increase the serum concentration of prednisolone |
Monitor for increased
adverse effects of prednisolone, consider dose reduction |
Lopinavir/Ritonavir + Rosuvastatin |
5 |
F |
CYP3A4 Inhibitors may
increase the serum concentration of rosuvastatin |
Start with the lowest
possible rosuvastatin dose, monitor for signs and symptoms of
toxicity |
Naproxen + Enoxaparin |
4 |
F |
NSAIDs3 may enhance
the anticoagulant effect of enoxaparin |
Monitor closely for signs and
symptoms of bleeding |
Naproxen + Heparin |
4 |
F |
NSAIDs may enhance the anticoagulant effect
of heparin |
Decrease the dose of heparin or NSAIDs |
Ibuprofen + Enoxaparin |
3 |
F |
NSAIDs may enhance the anticoagulant
effect of enoxaparin |
Monitor closely for signs and symptoms of
bleeding |
Indomethacin + Heparin |
3 |
F |
NSAIDs may enhance the anticoagulant
effect of heparin |
Decrease the dose of heparin or
NSAIDs |
Lopinavir/Ritonavir + Fentanyl |
3 |
F |
CYP3A4 inhibitors may increase
the serum concentration of fentanyl |
Monitor for increased adverse
effects of fentanyl, consider dose reduction |
Lopinavir/Ritonavir + Quetiapine |
3 |
F |
CYP3A4 inhibitors may
increase the serum concentration of quetiapine |
Consider using an
alternative or reduce the quetiapine dose to one-sixth of the original
dose |
Carbamazepine + Lopinavir/Ritonavir
|
2
|
F
|
Carbamazepine may decrease the serum concentration of lopinavir
|
Use a twice daily lopinavir/ritonavir regimen, monitor for reduced
effect of
lopinavir/ritonavir
|
Clopidogrel + Heparin |
2 |
F |
Antiplatelet agents may enhance the
anticoagulant effect of heparin |
Decrease the dose of heparin or
clopidogrel |
Indomethacin + Enoxaparin |
2 |
F |
NSAIDs may enhance the anticoagulant
effect of enoxaparin |
Monitor closely for signs and symptoms of
bleeding |
Midazolam + Fentanyl |
2 |
F |
Increased CNS depressant effects |
Close
monitoring for adverse effects |
Propofol + Fentanyl |
2 |
F |
Increase CNS depressant effects |
Close
monitoring for adverse effects |
Lopinavir/Ritonavir + Chlordiazepoxide |
2 |
F |
CYP3A4 inhibitors may
increase the serum concentration of chlordiazpoxide |
Monitor for
increased adverse effects of chlordiazpoxide |
Lopinavir/Ritonavir + Digoxin |
2 |
G |
Ritonavir may increase the serum
concentration of digoxin |
Reduce the digoxin dose (30% to 50%) or the
dosing frequency, Monitor digoxin levels |
Lopinavir/Ritonavir + Oxycodone |
2 |
F |
CYP3A4 inhibitors may increase
the serum concentration of oxycodone |
Monitor for increased adverse
effects of oxycodone |